4.6 Review

Neuroinflammation in frontotemporal dementia

Journal

NATURE REVIEWS NEUROLOGY
Volume 15, Issue 9, Pages 540-555

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-019-0231-z

Keywords

-

Funding

  1. National Health and Medical Research Council of Australia (NHMRC) [1132524, 1095127, 1140708, 1081916]
  2. University of Sydney
  3. NHMRC [1138223, 1079679, 1136241, APP1103258, 1107657]
  4. National Health and Medical Research Council of Australia [1140708, 1136241, 1138223, 1107657] Funding Source: NHMRC

Ask authors/readers for more resources

Frontotemporal dementia (FTD) refers to a group of progressive neurodegenerative disorders with different pathological signatures, genetic variability and complex disease mechanisms, for which no effective treatments exist. Despite advances in understanding the underlying pathology of FTD, sensitive and specific fluid biomarkers for this disease are lacking. As in other types of dementia, mounting evidence suggests that neuroinflammation is involved in the progression of FTD, including cortical inflammation, microglial activation, astrogliosis and differential expression of inflammation-related proteins in the periphery. Furthermore, an overlap between FTD and autoimmune disease has been identified. The most substantial evidence, however, comes from genetic studies, and several FTD-related genes are also implicated in neuroinflammation. This Review discusses specific evidence of neuroinflammatory mechanisms in FTD and describes how advances in our understanding of these mechanisms, in FTD as well as in other neurodegenerative diseases, might facilitate the development and implementation of diagnostic tools and disease-modifying treatments for FTD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available